About Low-density lipoprotein receptor class A domain-containing protein 3
Low-density lipoprotein receptor class A domain-containing protein 3 (LDLRAD3) is a protein
from Homo sapiens identified by UniProt accession
Q86YD5, 345 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Low-density lipoprotein receptor class A domain-containing protein 3 |
| UniProt accession | Q86YD5 |
| Gene | LDLRAD3 |
| Organism | Homo sapiens |
| Length | 345 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (49)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.49
- lymphocyte percentage of leukocytes · score 0.42
- blood protein measurement · score 0.40
- neutrophil percentage of leukocytes · score 0.33
- metabolite measurement · score 0.30
- non-small cell lung carcinoma · score 0.09
- gonorrhea · score 0.07
- neoplasm · score 0.07
- infection · score 0.04
- infect · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86YD5-F1 | alphafold | PREDICTED | 61.43 | — |
Amino-acid sequence (345 residues)
MWLLGPLCLL LSSAAESQLL PGNNFTNECN IPGNFMCSNG RCIPGAWQCD GLPDCFDKSD EKECPKAKSK CGPTFFPCAS GIHCIIGRFR CNGFEDCPDG SDEENCTANP LLCSTARYHC KNGLCIDKSF ICDGQNNCQD NSDEESCESS QEPGSGQVFV TSENQLVYYP SITYAIIGSS VIFVLVVALL ALVLHHQRKR NNLMTLPVHR LQHPVLLSRL VVLDHPHHCN VTYNVNNGIQ YVASQAEQNA SEVGSPPSYS EALLDQRPAW YDLPPPPYSS DTESLNQADL PPYRSRSGSA NSASSQAASS LLSVEDTSHS PGQPGPQEGT AEPRDSEPSQ GTEEV
Explore Low-density lipoprotein receptor class A domain-containing protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets